Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
RXII's Cash-to-Debt is ranked higher than
79% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. RXII: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
RXII' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.35  Med: No Debt Max: No Debt
Current: No Debt
0.35
No Debt
Equity-to-Asset 0.54
RXII's Equity-to-Asset is ranked lower than
89% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. RXII: 0.54 )
Ranked among companies with meaningful Equity-to-Asset only.
RXII' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.04  Med: 0.42 Max: 0.85
Current: 0.54
-1.04
0.85
Piotroski F-Score: 4
Altman Z-Score: -22.14
Beneish M-Score: 5.20
WACC vs ROIC
13.39%
449.07%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -8963.54
RXII's Operating Margin % is ranked lower than
96% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. RXII: -8963.54 )
Ranked among companies with meaningful Operating Margin % only.
RXII' s Operating Margin % Range Over the Past 10 Years
Min: -62440  Med: -21742.56 Max: -5250.38
Current: -8963.54
-62440
-5250.38
Net Margin % -8977.08
RXII's Net Margin % is ranked lower than
96% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. RXII: -8977.08 )
Ranked among companies with meaningful Net Margin % only.
RXII' s Net Margin % Range Over the Past 10 Years
Min: -83013.33  Med: -21673 Max: -5244.36
Current: -8977.08
-83013.33
-5244.36
ROE % -286.52
RXII's ROE % is ranked lower than
91% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. RXII: -286.52 )
Ranked among companies with meaningful ROE % only.
RXII' s ROE % Range Over the Past 10 Years
Min: -336.41  Med: -187.8 Max: -112.12
Current: -286.52
-336.41
-112.12
ROA % -155.88
RXII's ROA % is ranked lower than
92% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. RXII: -155.88 )
Ranked among companies with meaningful ROA % only.
RXII' s ROA % Range Over the Past 10 Years
Min: -603.25  Med: -142.35 Max: -72.95
Current: -155.88
-603.25
-72.95
ROC (Joel Greenblatt) % -3506.52
RXII's ROC (Joel Greenblatt) % is ranked lower than
76% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. RXII: -3506.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RXII' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11172.8  Med: -5174.59 Max: -3506.52
Current: -3506.52
-11172.8
-3506.52
3-Year Revenue Growth Rate -74.70
RXII's 3-Year Revenue Growth Rate is ranked lower than
88% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. RXII: -74.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RXII' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -77.7 Max: -68.2
Current: -74.7
3-Year EBITDA Growth Rate 57.40
RXII's 3-Year EBITDA Growth Rate is ranked higher than
95% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. RXII: 57.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RXII' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 57.4  Med: 58.9 Max: 63
Current: 57.4
57.4
63
3-Year EPS without NRI Growth Rate 58.80
RXII's 3-Year EPS without NRI Growth Rate is ranked higher than
94% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. RXII: 58.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RXII' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 54.5  Med: 60.15 Max: 66.6
Current: 58.8
54.5
66.6
GuruFocus has detected 4 Warning Signs with RXi Pharmaceuticals Corp RXII.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RXII's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

RXII Guru Trades in Q2 2016

Jim Simons 142,580 sh (+49.94%)
» More
Q3 2016

RXII Guru Trades in Q3 2016

Jim Simons 181,780 sh (+27.49%)
» More
Q4 2016

RXII Guru Trades in Q4 2016

Jim Simons 229,980 sh (+26.52%)
» More
Q1 2017

RXII Guru Trades in Q1 2017

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:RXII

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

RXi Pharmaceuticals Corp does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:TSXV:BCT, ROCO:6487, TSXV:RVV, LSE:SALV, ASX:PIQ, XCNQ:VP, ASX:RNO, NAS:EARS, ASX:SIE, OSTO:2CUREX, NAS:HTBX, OTCPK:LIXT, XCNQ:NSHS, AMEX:OGEN, ASX:LCT, XSAT:EUCI, XCNQ:ORTH, XTAE:XTL, NAS:TENX, XPAR:ALNOX » details
Traded in other countries:44R2.Germany,
Headquarter Location:USA
RXi Pharmaceuticals Corp is principally engaged in developing therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs.

RXi Pharmaceuticals Corp is a US-based clinical-stage company. It is principally engaged in developing therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The clinical development program of the company includes RXI-109, a sd-rxRNA for the treatment of dermal and ocular scarring, and Samcyprone, for the treatment of warts. The pipeline product of the company includes RXI-109, Immuno-oncology cell therapy, samcyprone, RXI-231, and RXI-185. The pipeline programs focus on dermatology, including cosmetic product development, ophthalmology, and cell-based cancer immunotherapy.

Top Ranked Articles about RXi Pharmaceuticals Corp

RXi Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells for the Advancement of Immuno-Oncology Therapeutics for Solid Tumors
RXi Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
RXi Pharmaceuticals to Webcast Second Quarter 2018 Financial Results on Tuesday, August 14, 2018
RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarring
BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of sd-rxRNA Drug Candidate for the Treatment of Spinal Cord Injury
RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone™ for the Treatment of Common Warts
RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics with Iovance's Tumor Infiltrating Lymphocytes (TILs) for Solid Tumors
RXi Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
RXi Pharmaceuticals Bolsters Strength of Dermatology Intellectual Property Estate Following Granting of Patent From USPTO

Ratios

vs
industry
vs
history
PB Ratio 1.58
RXII's PB Ratio is ranked lower than
72% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. RXII: 1.58 )
Ranked among companies with meaningful PB Ratio only.
RXII' s PB Ratio Range Over the Past 10 Years
Min: 0.92  Med: 3.55 Max: 48.78
Current: 1.58
0.92
48.78
PS Ratio 41.03
RXII's PS Ratio is ranked lower than
86% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RXII: 41.03 )
Ranked among companies with meaningful PS Ratio only.
RXII' s PS Ratio Range Over the Past 10 Years
Min: 40.35  Med: 235.48 Max: 1933.33
Current: 41.03
40.35
1933.33
EV-to-Revenue -0.88
RXII's EV-to-Revenue is ranked lower than
82% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. RXII: -0.88 )
Ranked among companies with meaningful EV-to-Revenue only.
RXII' s EV-to-Revenue Range Over the Past 10 Years
Min: -242.6  Med: 181.1 Max: 1124.5
Current: -0.88
-242.6
1124.5
Current Ratio 2.11
RXII's Current Ratio is ranked lower than
88% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. RXII: 2.11 )
Ranked among companies with meaningful Current Ratio only.
RXII' s Current Ratio Range Over the Past 10 Years
Min: 0.48  Med: 4.84 Max: 11.98
Current: 2.11
0.48
11.98
Quick Ratio 2.11
RXII's Quick Ratio is ranked lower than
84% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. RXII: 2.11 )
Ranked among companies with meaningful Quick Ratio only.
RXII' s Quick Ratio Range Over the Past 10 Years
Min: 0.48  Med: 4.84 Max: 11.98
Current: 2.11
0.48
11.98

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -122.70
RXII's 3-Year Average Share Buyback Ratio is ranked lower than
95% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. RXII: -122.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RXII' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -163.7  Med: -128.9 Max: -105.4
Current: -122.7
-163.7
-105.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.02
RXII's Price-to-Net-Cash is ranked lower than
92% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. RXII: 2.02 )
Ranked among companies with meaningful Price-to-Net-Cash only.
RXII' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.72  Med: 5.57 Max: 107.33
Current: 2.02
0.72
107.33
Price-to-Net-Current-Asset-Value 1.70
RXII's Price-to-Net-Current-Asset-Value is ranked lower than
73% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. RXII: 1.70 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
RXII' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.06  Med: 4.23 Max: 38.92
Current: 1.7
1.06
38.92
Price-to-Tangible-Book 1.59
RXII's Price-to-Tangible-Book is ranked lower than
64% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. RXII: 1.59 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RXII' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.01  Med: 4.02 Max: 34.72
Current: 1.59
1.01
34.72
Price-to-Median-PS-Value 0.17
RXII's Price-to-Median-PS-Value is ranked higher than
81% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. RXII: 0.17 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RXII' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.17  Med: 0.99 Max: 7.63
Current: 0.17
0.17
7.63

More Statistics

Revenue (TTM) (Mil) $0.10
EPS (TTM) $ -3.22
Beta1.72
Volatility59.25%
52-Week Range $1.12 - 7.70
Shares Outstanding (Mil)4.40

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 0 0 0
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -1.88 -1.23 -1.06
EPS without NRI ($) -1.88 -1.23 -1.06
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}